Am J Rhinol Allergy:鼻腔类固醇和抗组胺剂使用对总氧化应激和抗氧化状态的影响

2020-07-11 AlexYang MedSci原创

最近,有研究人员确定确定了过敏性鼻炎患者治疗后的总氧化状态(TOS)和总抗氧化状态(TAS)水平因病理生理而增加,并将其与治疗前水平进行了比较。

最近,有研究人员确定确定了过敏性鼻炎患者治疗后的总氧化状态(TOS)和总抗氧化状态(TAS)水平因病理生理而增加,并将其与治疗前水平进行了比较。

研究包括了84名临床诊断为过敏性鼻炎的患者,31名患者只接受了鼻腔类固醇治疗(糠酸莫米他松),53名患者同时接受鼻腔类固醇治疗和口服抗组胺药物治疗(糠酸莫米松+富马酸卢帕他定10mg)。研究发现,治疗后TAS水平均值没有发生显著变化,而TOS水平显著减少(P<0.01)。在只使用鼻腔类固醇的患者中,TAS和TOS值在治疗前后没有显著变化,而在同时接受鼻腔类固醇治疗和口服抗组胺药物治疗的患者中TOS值在治疗后显著减少(P<0.001)。另外,女性TOS值比男性显著更低,且在季节过敏性鼻炎中也比常年过敏性鼻炎低(均为P<0.05)。

最后,研究人员指出,在过敏性鼻炎患者中,同时使用鼻腔类固醇治疗和口服抗组胺药物治疗能够显著的减少氧化应激。因此,过敏性鼻炎治疗中加入抗组胺剂对治疗起着积极的作用。

原始出处:

Orhan Kemal Kahveci , Selçuk Kuzu , Mustafa Altıntaşet al. The Effect of Nasal Steroid and Antihistamine Use on Total Oxidative Stress and Antioxidant Status in the Treatment of Allergic Rhinitis. Am J Rhinol Allergy. 19 June 2020.

 

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1742162, encodeId=e1b81e42162a6, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Fri Jun 11 17:39:15 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313453, encodeId=e4d713134531e, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329392, encodeId=a8e11329392a7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445323, encodeId=99f61445323c0, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465865, encodeId=19e31465865d6, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802512, encodeId=e391802512d7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Jul 11 16:22:32 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1742162, encodeId=e1b81e42162a6, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Fri Jun 11 17:39:15 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313453, encodeId=e4d713134531e, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329392, encodeId=a8e11329392a7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445323, encodeId=99f61445323c0, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465865, encodeId=19e31465865d6, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802512, encodeId=e391802512d7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Jul 11 16:22:32 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1742162, encodeId=e1b81e42162a6, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Fri Jun 11 17:39:15 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313453, encodeId=e4d713134531e, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329392, encodeId=a8e11329392a7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445323, encodeId=99f61445323c0, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465865, encodeId=19e31465865d6, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802512, encodeId=e391802512d7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Jul 11 16:22:32 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
    2020-07-13 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1742162, encodeId=e1b81e42162a6, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Fri Jun 11 17:39:15 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313453, encodeId=e4d713134531e, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329392, encodeId=a8e11329392a7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445323, encodeId=99f61445323c0, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465865, encodeId=19e31465865d6, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802512, encodeId=e391802512d7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Jul 11 16:22:32 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1742162, encodeId=e1b81e42162a6, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Fri Jun 11 17:39:15 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313453, encodeId=e4d713134531e, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329392, encodeId=a8e11329392a7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445323, encodeId=99f61445323c0, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465865, encodeId=19e31465865d6, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802512, encodeId=e391802512d7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Jul 11 16:22:32 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
    2020-07-13 mnda
  6. [GetPortalCommentsPageByObjectIdResponse(id=1742162, encodeId=e1b81e42162a6, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Fri Jun 11 17:39:15 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313453, encodeId=e4d713134531e, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329392, encodeId=a8e11329392a7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445323, encodeId=99f61445323c0, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465865, encodeId=19e31465865d6, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Mon Jul 13 04:39:15 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802512, encodeId=e391802512d7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Jul 11 16:22:32 CST 2020, time=2020-07-11, status=1, ipAttribution=)]
    2020-07-11 医鸣惊人

    学习

    0

相关资讯

Am J Rhinol Allergy:屋尘螨舌下免疫治疗在儿童和成年人过敏性鼻炎治疗中的比较

到目前为止,只有很少的研究比较了SLIT在儿童和成年人中的治疗临床效果。另外,也缺乏与治疗相关其他因子的研究,包括免疫学参数和生活质量(QoL)。

盘点:鼻炎治疗小结

【1】Mol Immunol: 白藜芦醇介导的SIRT1激活能够减弱卵清蛋白诱导的过敏性鼻炎

Inflamm Res:IL18, FOXP3和IL13基因多态性和过敏性鼻炎风险相关性分析

过敏性鼻炎(AR)是一种鼻黏膜慢性炎症疾病。Th17细胞和调控T(Treg)细胞在AR的病理中具有作用。IL18, FOXP3和IL13是AR的发展过程的关键基因。然而,IL18, FOXP3和IL1

盘点:鼻炎研究小结

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与

Pediatr Allergy Immunol:蔬菜饮食模式能够预防轻度和永久过敏性鼻炎

饮食对过敏性鼻炎(AR)的影响、儿童中AR的严重度和是否饮食对AR具有依赖于遗传易感性的影响均不清楚。最近,有研究人员根据遗传风险评分(GRS),在儿童中调查了饮食模式和AR的相关性以及饮食对AR的影

Diabetologia:糖尿病相关的自身抗体与哮喘、湿疹和过敏性鼻炎的相关性研究

最近,有研究人员展现了胰岛素自身抗体、1型糖尿病前体与持续性哮喘、过敏性鼻炎和湿疹之间的关系。